Pharmaceutical industry – Page 39
-
Business
Vertex nabs rights to cystic fibrosis molecules
Deal with Parion, worth up to $1bn, gives firm worldwide rights to investigational treatments that complement Vertex’s existing cystic fibrosis drugs
-
Business
Opko deepens diagnostics with $1.5bn lab buyout
Taking over clinical diagnostics service provider BioReference Laboratories gives Opko a bigger avenue to distribute and market its diagnostic tests
-
BusinessBMS sues executive for joining rival company
Bristol-Myers Squibb’s lawsuit against its former immuno-oncology chief who left to work for AstraZeneca has implications for biopharma industry
-
Business
Takeda to consolidate vaccines business in Boston
Firm will close three recently-acquired US sites and shift operations to the growing pharmaceutical hub in Massachusetts
-
Business
Teva fined $1.2bn in pay-for-delay case
Company illegally blocked generic competition of sleep disorder drug, and settlement terms tighten up rules on anticompetitive behaviour
-
Business
Achillion partners with Janssen to boost hepatitis C pipeline
Development deal worth up to $1.1bn includes three investigational drugs aiming to extend treatment options in fast-moving market
-
Business
Actavis plan to thwart generics blocked
Company prevented from withdrawing original formulation of Alzheimer’s drug to force patients onto extended release version and extend patent exclusivity
-
Business
Endo to buy Par as generics consolidation continues
$8bn deal follows trend as drugmakers aim for economies of scale
-
Business
Canada sets climate target
Canada aims to cut greenhouse gas emissions from energy-intensive sectors by 30% from 2005 levels by 2030
-
Business
GSK commits to HIV research
Firm will partner with US university and cancels plan to sell its share of ViiV Healthcare joint venture
-
Business
Injunction blocks first US biosimilar
Despite regulatory approval, Amgen is delaying sales of Sandoz’s version of filgrastim
-
Business
FDA accused of violating drug company’s freedom of speech
Amarin says the regulator is stopping it from giving ‘truthful, not misleading’ information to doctors about its fatty acid drug
-
Business
Alexion to buy Synageva for rare disease drugs
$8.4bn deal gives firm access to enzyme drug currently under review with US and EU regulators
-
Business
Takeda offers $2.4bn to settle diabetes litigation
Aims to settle multiple outstanding lawsuits relating to Actos (pioglitazone) and bladder cancer
-
Business
Zoetis to sell or close 10 plants in cost-cutting drive
Animal health firm will slash product portfolio in a bid to save $300m annually
-
BusinessMerger creates biggest supplier of unlicensed drugs
Clinigen will buy Idis to consolidate different routes by which doctors can access medicines that are unavailable locally
-
BusinessGenerics firms in three-way takeover battle
Mylan is chasing Perrigo, while fending off advances from Teva
-
Business
Daiichi Sankyo steps out after Sun-Ranbaxy merger
Ranbaxy’s Japanese owner has sold off its stake in the merged company, but will retain its business partnership
-
Business
Generics giant Mylan offers $30 billion for Perrigo
Mylan makes ambitious takeover offer just weeks after Abbott aquisition closes